NightingaleFor Clinical Research Organizations
CRO Partnership ProgramLive at Emory University

Deliver modern data. Under your brand.

Nightingale is software that sits between the systems a study collects data from and the database it reports into, checking and cleaning every value on the way through. We are not selling you software. We are looking for a small number of CRO partners to carry it into their portfolio as their own capability, priced and branded by them, with the delivery work done by us. Finishing a study sooner is worth money to your client, and it is worth more than that to the patients waiting on the treatment.

$340Kcontracted
11channel partners
~97Kqueries per Phase III
0 FTEcommitment · no platform fee
GxPaudit complete
01 · Why CROs, why now

Sponsors are asking for data you still deliver by hand.

The FDA launched Real-Time Clinical Trials in April 2026, and ICH E6(R3) is in force. Sponsors will expect their CRO to have an answer.

~97,000
queries per Phase III study your team works 6
58%
of those queries change no data at all 6
~69%
of sites juggle six or more sponsor systems 4
8.23%
error rate when records are re-keyed by hand 5
Lab manuals, reconciled by hand

A trial with five labs has five manuals, each with its own units and ranges, checked against the protocol by a scientist.

Every site is a different setup

Under E6(R3) the site owns its records and chooses its systems. A 40-site trial is 40 setups with no overlap.

Provenance you must now prove

E6(R3) requires showing where every value came from and a published data-flow diagram. Nightingale produces both.

The regulatory clock sponsors are asking about

Dec 2023FDA digital health guidanceFirst system data lands in is the official source
Sep 2025ICH E6(R3) in forceProve where every value came from
Jan 2026FDA + EMA AI principlesAI needs data you can trace back
Apr 2026Real-Time Clinical TrialsContinuous data to the regulator
Sep 2026ARPA-H SURPASSFederal funding for real-time, adaptive trials
Jan 2027E6(R3) Annex 2Same rules for decentralized trials and RWE
02 · The product

What you would be delivering.

A Phase III study generates around 97,000 queries, and more than half change no data at all 6. Nightingale stops them being created.

✓Validate the study first

Protocol, lab and pharmacy manuals, consent, questionnaires and eCRF guidelines reconciled before enrollment.

⇄Data from any source

Devices, patient apps, labs, paper and other systems, into whichever database the study uses.

▤Submission-ready output

Delivered in the format regulators expect, with a record of where every value came from and what was done to it.

≡No AI deciding your data

Fixed rules decide every value, so the same input always gives the same result and anyone can check the rule.

WHAT GOES INNIGHTINGALE · RUNS FOR THE WHOLE TRIALWHAT COMES OUT The study's rulebook Protocol · endpoints Lab & pharmacy manuals Consent · questionnaires Data-entry guide · output spec The regulators' rulebook FDA guidance · Part 11 EMA (EU) · ICH E6(R3) The data · each site's own Hospital records (EHR) Labs · imaging · pharmacy Wearables · devices · apps Telehealth visits Handwritten notes · paper Real-world evidence 1 · Check the rulebook Study documents vs each other vs FDA / EMA / ICH → every conflict flagged 2 · Inventory What already exists, incl. real-world evidence 3 · Find the gap Sponsor's required output vs what exists → what to collect 4 · Run the data · fixed rules map field → convert unit → check range → deliver Same input always gives the same output. No retyping. AI reads documents; fixed rules decide. 5 · Watch it daily Gap re-checked on live data. Advance notice if an endpoint is at risk. 6 · Prove every step Audit trail per data point: created, verified, or fixed & flagged. ↻ steps 4-6 repeat every day until the last data point 7 · Close and submit Endpoints met? If not, why, and what to enroll. Submission-ready package for the regulator. 8 · Every trial feeds the cross-trial data layer Consented, de-identified, identically structured. The basis for Layer 3. Sponsor's EDCMedidata · Veeva · Oracle · any Sponsor's output formatExactly as specified Audit recordEvery value, every step RegulatorReal-time feed · submission package Storage stays with the sponsor. Layer 3 · synthetic control arms · digital twins · cross-trial discovery · new treatments
Hover a stage to trace its inputs and outputs; click to see an example. Every stage produces something you can open and check.
1

Check the rulebook

Every study document vs each other and vs FDA, EMA, ICH. Conflicts flagged before enrollment.

ExampleProtocol in kilometers, lab manual in miles. Flagged on day one, not month four.
2

Inventory what exists

Records, prior labs, device history and paper, filtered to what counts.

ExampleTwo years of blood pressure already in the chart get structured and counted.
3

Find the gap

What the sponsor needs minus what exists = what to collect.

ExampleECGs needed at weeks 4, 12, 24; records cover week 4 for a third of patients.
4

Run the data

Map, convert, check, deliver into the EDC. No retyping.

ExampleWatch reports 10 miles; 16.09 km lands in the right field, with the conversion recorded.
5

Watch it daily

Gap re-checked on live data; early warning when an endpoint is at risk.

ExampleSite 17's ECG timestamps drift 40 minutes. Flagged in week 3, not at lock.
6

Prove every step

An audit trail for every data point, created or verified.

ExampleWhere did this glucose value come from? One click: device, time, conversion, reviewer.

A source link proves a number is real. It does not prove it is right. Every value carries two things: where it came from, and the rule that produced it, checked against the protocol, the lab manual and the consent form before the first patient. When one of those documents changes, the values it governs are flagged for re-review rather than quietly inheriting the old definition.

03 · The partnership

Your capability. Our engineers.

A partner model, not a vendor contract. You own the client relationship and the pricing.

AWhite-labeled by default

Your brand, not ours.

Sponsors see your capability, not a third-party logo. That is the point of doing this with us rather than buying a tool.

BYou set the price

You keep the spread.

We quote a partner rate. You price the work at what it is worth to your client and keep the difference.

CDefault status, not headcount

No FTEs, no platform fee.

Nightingale becomes the data layer you propose by default, with a minimum number of studies a year.

Who does what

Your CROOwns the client
  • Sponsor relationship and study management
  • Pricing and the proposal
  • Your brand on the capability
NightingaleDoes the data work
  • Rulebook check before enrollment
  • Source connections and the pipeline
  • Daily monitoring and the audit trail
  • Forward-deployed engineers, scoped per protocol
SitesNothing new
  • No new logins or tools
  • Never a customer
  • Re-keying workload goes down
04 · Partner economics

Estimate the hours you get back.

Margin on both sides: fewer delivery hours on work you already bill, plus the spread between our partner rate and the price you set.

Data-management hours freed

10
5
12
$70
Hours freed per year
·

Based on 70% of that work removed, the figure we measure with you on the first study.

Cost of those hours
·

Capacity for more studies, or margin on work you already bill

Full-time equivalents
·

at 2,080 hours per FTE year

Defaults: ~12 hours a week per data manager on query and reconciliation work 9, ~$70 an hour 8, and 70% of manual work removed, our design target, measured against your baseline on the first study. Your spread on the partner rate comes on top.

Where the margin comes from

Margin on the study price
Nightingale partner rateYour spread
What you pay usWhat you keep

Illustrative proportions; your rate card sets the real numbers.

Delivery hours on work you already bill
Manual data work today
With Nightingale

Forward-deployed engineers stand it up inside your operation, scoped per protocol to your timeline.

05 · Trials in scope

How many trials this applies to.

The trials this applies to, counted from the public registry rather than estimated from market reports.

35,000+
new studies registered every year 13
~20,000
interventional trials a year we can serve, our estimate 13
~28.5%
of interventional trials are industry-sponsored; the rest are academic, hospital or government 21
Every phase
Phase I to IV, plus device, diagnostic and software studies
In scope

Interventional trials of any phase, and device, diagnostic or digital-health studies, that collect data from more than one electronic source and report into a study database.

Best fit today

Studies with wearables, home visits, several labs or many sites, where reconciling sources by hand is the bottleneck.

Out of scope

Registry-only and observational studies with a single data source, where there is little to reconcile.

The trial pool keeps growing: registrations have risen every year since the registry opened in 2000 13. Counts are from public registry data; the in-scope figure is our estimate, not a registry statistic.

06 · What it wins you

Bids you cannot defend today.

A capability on your side of the table, not a line item on your cost sheet.

◷Ready for continuous data

When a sponsor asks how you deliver data as it happens, the answer is that nothing is typed in by hand.

◎Studies with more data

Bid on studies using wearables, home visits and constant reporting, without building the systems yourself.

⊞Predictable pricing

Based on participants, number of data sources and study length, all known at bid time.

↗Margin on both sides

Fewer delivery hours on work you already bill, plus the spread on the partner rate.

Questions sponsors put in your bid, answered

The sponsor asks
You answer, with Nightingale
How will you meet real-time data expectations?
Data flows from every source into the EDC in minutes, not 8.1 days 3, with no re-keying at sites.
Can you prove where every value came from?
An audit trail on every data point, created or verified, plus the E6(R3) data-flow diagram.
Can you run a decentralized, wearable-heavy protocol?
Devices, ePRO, apps, labs and paper connect once, reconciled across all 40 site setups.
Will you use existing patient records?
Existing records are inventoried and structured as real-world evidence, which the FDA encourages.
Is AI changing our data?
No AI decides your data. Fixed rules do, and the same input always gives the same result.
What will it cost, and will it hold?
Priced on participants, sources and duration, so the number is reproducible at bid time and scales with the study.
07 · Partner or build

Why partner rather than build it in-house.

You get the capability on your side of the table without an engineering program of your own.

1Your model is billed in hours

Building a tool that removes those hours competes with your own revenue. Partnering lets you keep the margin instead.

2Neutral to every EDC

Sponsors run Medidata, Veeva, Oracle and others. The layer works with whichever one a study already uses.

3A library that compounds

Every trial teaches the system another lab format and device export, across sponsors. One CRO's studies cannot rebuild it.

4Faster each time

Deployment drops from about four weeks on a first trial to about two on the next, starting from existing connectors.

What building it costs, on conservative numbers

$2.1M
to build and run it for three years
11 months
before the first study can use it
6 engineer-years
of your own people, on this instead of client work
$177K
cost per study at four studies a year
Initial build: four engineers for eleven months, loaded at $180K a year
$660K
Validation and qualification: five person-months, and again after every change
$75K
Upkeep: one engineer for every eight source types, plus two person-months a year of revalidation, years two and three
$420K
Hosting, environments and processing, three years
$180K
Data work still done per study, eighty person-days each, twelve studies
$780K
Three-year total, before the first overrun
$2.1M
Building it yourself
Time to the first study11 months
Engineers you hire and hold4 to 5
Cost per study, four a year$177K
Validation evidenceYours to write and defend
New device or EHR versionYour backlog
If it slips six monthsCost rises, capability does not
Partnering with Nightingale
Time to the first study4 weeks
Engineers you hire and hold0
Cost per study, four a yearPartner rate, set per study
Validation evidenceGxP audited, provided with the study
New device or EHR versionOurs to carry
If a study does not startYou pay nothing for it

Figures use public salary benchmarks and conservative effort: four engineers at $180K fully loaded, eleven months to a working version, five person-months of computer system validation, eight source types maintained, eighty person-days of data work per study, four studies a year, 220 working days a year. They exclude hiring time, protocol amendments, scope creep and the revenue at risk during the build, all of which push a build higher. Run at high enough volume, an in-house build can be cheaper in cash once it works; we will run the numbers with you either way.

08 · On a study

What changes on a large Phase III.

The work your data-management team does by hand today, and what it looks like with the layer in place.

Without Nightingale
With Nightingale
Sources to reconcile
14 sources · 120 site setupsfive lab manuals, by hand
14 sources · connected onceall manuals reconciled on day one
Visit → data in database
8.1 daysre-keyed by coordinators
Minutesautomated, no retyping
Queries over the trial
~150,00058% change nothing
~60,000queries from conflicting study documents never happen
Errors from re-keying
~250,000 values8.23% of ~3M hand-entered fields
~0 · source errors flaggedevery value carries its origin
Cleanup before database lock
90 daystypical for a trial this size
~10 daysdata was clean as it arrived
Data-management labor
$1.3Mten-person team, three years
$0.4M70% of manual work removed
Cost of the lock delay
$50M$5M direct + $45M forgone revenue
$5.6M80 days recovered
Audit trail at submission
Partialreconstructed after the fact
Completeevery value, every step, E6(R3)-ready
Without
36 months of trial+3 mo to lock
With
36 months of trial~80 days to market sooner

Illustrative: a 2,000-patient, 120-site, 14-source, three-year Phase III modeled from the published figures in the appendix. Design targets under validation, not measured averages.

09 · How we start

From a first call to your portfolio.

How we startFour steps to a partnership.
Step 01Portfolio Review

A 30-minute call on your active trials, sponsor mix, and where data work is costing you today.

Step 02Data Flow Review

A complimentary hands-on review of one active trial: sources, cleanup steps, and EDC targets.

Step 03Terms and Scope

Written findings, partner rate card, white-label terms, and the annual study minimum that sets default status.

Step 04Parallel Run

Baseline a comparable trial, run Nightingale alongside on one study, then compare the number of queries, how many are resolved first time, and the lock date before you commit.

10 · Where we are today

Live, audited, and adding a small number of partners.

Where we are today

EmpowerMBC at Emory University, a Gilead-funded oncology study under Dr. Lauren McCullough, is our flagship live deployment and the reference we will put on a call. Our GxP vendor audit is complete; SOC 2 Type II is in progress. We will baseline on your study before we claim anything.

Traction

$340K contracted across signed agreements, the majority through a CRO partner rather than direct: Emory University plus two medical-device trials via Thinq CRO. Harvard iLab company, 11 signed channel partners, and onboarding into the Georgia CTSA Program.

$340K
contracted, majority via a CRO partner
11
signed channel partners
GxP
vendor audit complete
SOC 2
Type II in progress
11 · Partner FAQ

The questions CROs ask.

Tap a question for the full answer.
In shortNeutral across every EDC, and built for site-controlled sources.
In shortYour brand, your client relationship.
In shortA study minimum, not headcount or a platform fee.
In shortWe baseline on your study before we claim anything.
In shortAudited, aligned, and live on real patient data.
In shortSource links show where a value came from. We show what it means, and tell you when that changes.
In shortIt removes low-value work; your team decides where the hours go.
In shortWhatever the study already uses.
12 · Get in touch

Start with a portfolio review.

Thirty minutes on your active trials, sponsor mix, and where data work is costing you today.

Yash Vagal
Co-Founder and CEO, Nightingale

Pick a time that works for you. We will come prepared to talk through your portfolio and whether a partnership fits.

30-minute callVideo call
Book a portfolio review

What happens next

1Portfolio review

A 30-minute call on your active trials and sponsor mix.

2Data flow review

A complimentary hands-on review of one active trial.

3Terms and scope

Written findings, partner rate card and white-label terms.

13 · Appendix · sources

Sources behind every figure.

Show all 20 sources
  1. Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
  2. Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
  3. Tufts CSDD, eClinical Landscape Study: 257 organizations; median 8.1 days from patient visit to EDC entry.
  4. Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
  5. Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
  6. Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
  7. Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
  8. Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
  9. Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
  10. Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
  11. IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
  12. Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
  13. ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
  14. ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
  15. ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
  16. FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026); HHS and ARPA-H SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), solicitation ARPA-H-SOL-26-164 (30 Sep 2026).
  17. Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
  18. Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
  19. Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
  20. FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
  21. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.